Domperidone, a new dopamine antagonist

M C Champion, M Hartnett, M Yen, M C Champion, M Hartnett, M Yen

Abstract

Domperidone is a dopamine antagonist that has recently been released in Canada. Unlike metoclopramide hydrochloride, the other available dopamine antagonist, it does not readily enter the central nervous system. Domperidone acts as both an antiemetic and an upper gastrointestinal tract prokinetic agent. It is rapidly absorbed after oral administration, and few side effects have been reported. Domperidone has been approved for use in Canada for the symptomatic management of upper gastrointestinal tract motility disorders and to prevent gastrointestinal symptoms associated with the use of dopamine agonist agents in Parkinson's disease. The pharmacologic features, indications and side effects of domperidone are reviewed.

References

    1. Lancet. 1979 Mar 17;1(8116):570-2
    1. Am J Gastroenterol. 1985 Dec;80(12):1008-16
    1. Postgrad Med J. 1979;55 Suppl 1:24-7
    1. Postgrad Med J. 1979;55 Suppl 1:28-9
    1. J Int Med Res. 1979;7(2):158-61
    1. J Int Med Res. 1981;9(2):143-7
    1. Neurology. 1981 Jun;31(6):662-7
    1. Ann Intern Med. 1983 Jan;98(1):86-95
    1. Drugs. 1982 Nov;24(5):360-400
    1. Digestion. 1983;27(4):214-7
    1. Dig Dis Sci. 1985 Jan;30(1):1-9
    1. Br Med J (Clin Res Ed). 1985 Jan 12;290(6462):160
    1. J Pediatr. 1985 Feb;106(2):311-6
    1. Br J Clin Pharmacol. 1984 Dec;18(6):959-62
    1. Scand J Gastroenterol. 1985 Mar;20(2):150-4
    1. Helv Paediatr Acta. 1984 Aug;39(3):285-8
    1. Postgrad Med J. 1979;55 Suppl 1:11-4

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe